Cargando…
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
BACKGROUND: A prospective, multicenter trial was undertaken to assess the activity, safety, and quality of life of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer (MBC). PATIENTS AND METHODS: Fifty-two wo...
Autores principales: | Palumbo, Raffaella, Sottotetti, Federico, Trifirò, Giuseppe, Piazza, Elena, Ferzi, Antonella, Gambaro, Anna, Spinapolice, Elena Giulia, Pozzi, Emma, Tagliaferri, Barbara, Teragni, Cristina, Bernardo, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404936/ https://www.ncbi.nlm.nih.gov/pubmed/25931813 http://dx.doi.org/10.2147/DDDT.S79563 |
Ejemplares similares
-
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015) -
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
por: Palumbo, Raffaella, et al.
Publicado: (2019) -
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
por: Fabi, Alessandra, et al.
Publicado: (2015) -
nab-Paclitaxel (Abraxane(®)): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors
por: Iglesias, J
Publicado: (2009) -
Patterns of treatment and outcome of palbociclib plus endocrine
therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast
cancer: a real-world multicentre Italian study
por: Palumbo, Raffaella, et al.
Publicado: (2021)